PE20240048A1 - Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma - Google Patents
Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la mismaInfo
- Publication number
- PE20240048A1 PE20240048A1 PE2023001494A PE2023001494A PE20240048A1 PE 20240048 A1 PE20240048 A1 PE 20240048A1 PE 2023001494 A PE2023001494 A PE 2023001494A PE 2023001494 A PE2023001494 A PE 2023001494A PE 20240048 A1 PE20240048 A1 PE 20240048A1
- Authority
- PE
- Peru
- Prior art keywords
- preparation
- crystalline form
- melanocortin receptor
- receptor agonist
- agonist compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 229940117029 Melanocortin receptor agonist Drugs 0.000 title 1
- 239000000336 melanocortin receptor agonist Substances 0.000 title 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 abstract 2
- 102000004378 Melanocortin Receptors Human genes 0.000 abstract 1
- 108090000950 Melanocortin Receptors Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940047889 isobutyramide Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A LA FORMA CRISTALINA I DEL HIDRATO DE CLORHIDRATO DE N-((3S,5S)-1-((3S,4R)-1-(TER-BUTIL)-4-(4-CLOROFENIL)PIRROLIDIN-3-CARBONIL)-5-(MORFOLIN-4-CARBONIL)-PIRROLIDIN-3-IL)-N-((1S,4R)-4-METILCICLOHEXIL)ISOBUTIRAMIDA CUYO PATRON DE DIFRACCION DE POLVO DE RAYOS X PRESENTA PICOS CARACTERISTICOS CON LOS SIGUIENTES ANGULOS DE DIFRACCION (VALORES 2THETA) DE: 7.19±0.2°, 9.58±0.2°, 10.87±0.2°, 12.50±0.2°, 14.73±0.2°, 17.38±0.2°, 18.22±0.2°, 18.59±0.2°, 19.03±0.2°, 20.61±0.2°, 21.14±0.2°, 21.82±0.2°, 22.42±0.2°, 23.18±0.2°, 24.15±0.2°, 24.92±0.2°, 25.55±0.2°, 27.04±0.2°, 28.75±0.2° Y 29.85±0.2°. TAMBIEN SE REFIERE A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE. DICHO COMPUESTO ES AGONISTA DE UN RECEPTOR DE MELANOCORTINA SIENDO UTIL EN EL TRATAMIENTO DE OBESIDAD, DIABETES.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200142396 | 2020-10-29 | ||
| PCT/KR2021/015469 WO2022092909A1 (ko) | 2020-10-29 | 2021-10-29 | 멜라노코르틴 수용체 작용제 화합물의 결정형 i 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240048A1 true PE20240048A1 (es) | 2024-01-09 |
Family
ID=81384109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001494A PE20240048A1 (es) | 2020-10-29 | 2021-10-29 | Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230373984A1 (es) |
| EP (1) | EP4219472A4 (es) |
| JP (1) | JP2023548327A (es) |
| KR (2) | KR102672624B1 (es) |
| CN (1) | CN116507615A (es) |
| AU (1) | AU2021367713B2 (es) |
| CA (1) | CA3195298A1 (es) |
| CL (1) | CL2023001223A1 (es) |
| CO (1) | CO2023006515A2 (es) |
| IL (1) | IL302427A (es) |
| MX (1) | MX2023004655A (es) |
| PE (1) | PE20240048A1 (es) |
| WO (1) | WO2022092909A1 (es) |
| ZA (1) | ZA202305594B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024501828A (ja) * | 2020-12-22 | 2024-01-16 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法 |
| EP4249485A4 (en) * | 2020-12-22 | 2024-05-15 | Lg Chem, Ltd. | CRYSTALLINE FORM III OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR |
| JP2024500966A (ja) * | 2020-12-22 | 2024-01-10 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法 |
| WO2022235104A1 (ko) * | 2021-05-06 | 2022-11-10 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 v 및 이의 제조방법 |
| BR112023022432A2 (pt) * | 2021-05-07 | 2024-01-09 | Lg Chemical Ltd | Formas cristalinas iv de sais de ácidos orgânicos de composto agonista do receptor de melanocortina, seus metódos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas |
| CA3217198A1 (en) * | 2021-05-07 | 2022-11-10 | Lg Chem, Ltd. | Sulfate crystals of melanocortin receptor agonist compound and method of producing same |
| KR20220152166A (ko) * | 2021-05-07 | 2022-11-15 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물과 바닐린의 공결정 및 이의 제조방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1187614A4 (en) * | 1999-06-04 | 2005-06-22 | Merck & Co Inc | SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS |
| JP2004521117A (ja) * | 2001-01-23 | 2004-07-15 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン |
| AR044510A1 (es) | 2003-04-14 | 2005-09-14 | Merck & Co Inc | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
| CA2545644C (en) | 2003-11-12 | 2011-11-01 | Lg Life Sciences Ltd. | Melanocortin receptor agonists |
| KR20080007046A (ko) * | 2006-07-14 | 2008-01-17 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
| TWI332501B (en) | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| AU2018219880A1 (en) | 2017-02-08 | 2019-08-29 | Tilray, Inc. | Methods and apparatus for low-pressure radiant energy processing of cannabis |
| PE20220766A1 (es) * | 2019-11-07 | 2022-05-16 | Lg Chemical Ltd | Agonistas de receptor de melanocortina-4 |
-
2021
- 2021-10-29 WO PCT/KR2021/015469 patent/WO2022092909A1/ko active Application Filing
- 2021-10-29 KR KR1020210146188A patent/KR102672624B1/ko active IP Right Grant
- 2021-10-29 JP JP2023526438A patent/JP2023548327A/ja active Pending
- 2021-10-29 CN CN202180073226.2A patent/CN116507615A/zh active Pending
- 2021-10-29 US US18/251,084 patent/US20230373984A1/en active Pending
- 2021-10-29 IL IL302427A patent/IL302427A/en unknown
- 2021-10-29 PE PE2023001494A patent/PE20240048A1/es unknown
- 2021-10-29 MX MX2023004655A patent/MX2023004655A/es unknown
- 2021-10-29 AU AU2021367713A patent/AU2021367713B2/en active Active
- 2021-10-29 CA CA3195298A patent/CA3195298A1/en active Pending
- 2021-10-29 EP EP21886903.0A patent/EP4219472A4/en active Pending
-
2023
- 2023-04-27 CL CL2023001223A patent/CL2023001223A1/es unknown
- 2023-05-17 CO CONC2023/0006515A patent/CO2023006515A2/es unknown
- 2023-05-24 ZA ZA2023/05594A patent/ZA202305594B/en unknown
-
2024
- 2024-05-31 KR KR1020240071408A patent/KR20240085230A/ko active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220057470A (ko) | 2022-05-09 |
| KR102672624B1 (ko) | 2024-06-07 |
| KR20240085230A (ko) | 2024-06-14 |
| AU2021367713A9 (en) | 2024-04-18 |
| CN116507615A (zh) | 2023-07-28 |
| ZA202305594B (en) | 2024-09-25 |
| CA3195298A1 (en) | 2022-05-05 |
| CO2023006515A2 (es) | 2023-07-31 |
| CL2023001223A1 (es) | 2023-11-03 |
| AU2021367713A1 (en) | 2023-06-01 |
| MX2023004655A (es) | 2023-05-18 |
| EP4219472A4 (en) | 2024-03-13 |
| EP4219472A1 (en) | 2023-08-02 |
| JP2023548327A (ja) | 2023-11-16 |
| AU2021367713B2 (en) | 2024-01-25 |
| US20230373984A1 (en) | 2023-11-23 |
| WO2022092909A1 (ko) | 2022-05-05 |
| IL302427A (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240367A1 (es) | Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20240048A1 (es) | Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20240124A1 (es) | Forma cristalina ii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20240366A1 (es) | Forma cristalina iii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20220766A1 (es) | Agonistas de receptor de melanocortina-4 | |
| EA202090029A1 (ru) | Твердая композиция карипразина для орального введения | |
| CL2008000127A1 (es) | Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos | |
| RU2017111590A (ru) | Кристаллические формы 2-(4-(4-этокси-6-оксо-1,6-дигидропиридин-3-ил)-2-фторфенил)-n-(5-(1,1,1-трифтор-2- метилпропан-2-ил)изоксазол-3-ил)ацетамида | |
| CL2021001325A1 (es) | Ureas cíclicas. | |
| PE20061070A1 (es) | FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN | |
| JP2010514832A5 (es) | ||
| DK1853266T3 (da) | 2S,4R-Ketoconazol til behandling af diabetes, metabolsk syndrom og øvrige tilstande | |
| EA201071054A1 (ru) | Твердый препарат, растворяющийся во рту | |
| ECSP088120A (es) | Derivados de piridazinona como agonistas del receptorde la hormona tiroidea | |
| PE20090912A1 (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
| AR120703A1 (es) | Formas sólidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-amina de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico | |
| CY1124616T1 (el) | Θεραπεια της μετα-βαριατρικης υπογλυκαιμιας με εξενδινη(9-39) | |
| RU2016114540A (ru) | Соль азотсодержащего гетероциклического соединения или ее кристаллическая форма, фармацевтическая композиция и ингибитор flt3 | |
| JP2014062126A5 (es) | ||
| PH12014502331B1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| MA43833B1 (fr) | Nouvelle forme cristalline de sel de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine | |
| IL313292A (en) | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND TYPE II DIABETES | |
| CL2023000534A1 (es) | Antagonista cristalino del receptor edg-2 y métodos de fabricación | |
| MX2019001380A (es) | Cristales de derivado de amina ciclica y uso farmaceutico de los mismos. | |
| CL2020001928A1 (es) | Formas cristalinas del antagonista del receptor cxcr7 ácido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxílico (1-pirimidin-2-il-ciclopropil)-amida. |